A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

Phase 1 Completed 77 enrolled Janssen Research & Development, LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the effect of treatment with guselkumab in participants with familial adenomatous polyposis (FAP) on rectal/pouch polyp burden.

Timeline

Start: 2018-11-19
Primary completion: 2021-09-13
Completion: 2022-03-23

Publications

Stone JK, Mehta NA, Singh H, El-Matary W, Bernstein CN. Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome. Fam Cancer. 2023 Oct;22(4):413-422. doi: 10.1007/s10689-023-00334-3. Epub 2023 Apr 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Guselkumab	Monoclonal antibody	100 mg	Subcutaneous
Subject	Guselkumab	Monoclonal antibody	300 mg	Subcutaneous

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

Summary

Timeline

Publications

Drugs

Indications